Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Severe acute pancreatitis (AP) is a pathology with high morbidity and mortality. Portosplenomesenteric vein thrombosis is a well-known local complication of AP with a variable incidence, which can reach up to 50% in case of severe AP. However, there is no specific recommendation regarding the management of Portosplenomesenteric vein thrombosis. By analogy to all venous thrombosis, the European Society of Gastroenterology recommends curative anticoagulation. However, the efficacy of curative anticoagulation has never been evaluated by prospective studies. In addition, bleeding complications during AP occur in approximately 10% of patients and are associated with a poor prognosis.
The investigators wish to conduct an observational multi-center study with epidemiologic aims, including all patients admitted for AP and with a diagnosis of portosplenomesenteric vein thrombosis. The aim of this study is to evaluate the therapeutic management of these patients, the efficacy and safety of anticoagulant treatment for the treatment of Portosplenomesenteric vein thrombosis, and their outcomes.
The investigators will include prospectively all patients admitted for AP with a computed tomography diagnosis of portosplenomesenteric vein thrombosis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| observational study | Other | patients admitted for AP with portosplenomesenteric vein thrombosis. |
| Measure | Description | Time Frame |
|---|---|---|
| incidence of anticoagulation therapy | incidence defined as : the ratio of the number of patients on curative anticoagulant therapy to the number of patients admitted with AP and portosplenomesenteric vein thrombosis during the inclusion period | up to 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| evaluate the outcomes of Number of patients admitted for AP with portosplenomesenteric vein thrombosis | up to 12 months | |
| hospital mortality at D28 | evaluate the hospitality mortality at D28 of patients admitted for AP with portosplenomesenteric vein |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients admitted for AP with portosplenomesenteric vein thrombosis
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GARRET Charlotte, MD | University hospital of Nantes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Nantes | Nantes | France |
Not provided
| ID | Term |
|---|---|
| D019283 | Pancreatitis, Acute Necrotizing |
| D010195 | Pancreatitis |
| D010182 | Pancreatic Diseases |
| D006470 | Hemorrhage |
| ID | Term |
|---|---|
| D004066 | Digestive System Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D019370 | Observation |
| ID | Term |
|---|---|
| D008722 | Methods |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 28 |
| hospital mortality at D90 | evaluate the hospitality mortality at D90 of patients admitted for AP with portosplenomesenteric vein | Day 90 |
| hospital mortality at 6 months | evaluate the hospitality mortality at 6 months of patients admitted for AP with portosplenomesenteric vein | 6 months |
| hospital mortality at 12 months | evaluate the hospitality mortality at 12 months of patients admitted for AP with portosplenomesenteric vein | 12 months |
| incidence of portal cavernoma | evaluate the incidence of portal cavernoma of patients admitted for AP with portosplenomesenteric vein | up to 12 months |
| incidence of type 2 diabetes secondary to AP | evaluate the incidence of type 2 diabetes secondary to AP of patients admitted for AP with portosplenomesenteric vein | up to 12 months |
| incidence of occurrence of malabsorption | evaluate the incidence of occurrence of malabsorption of patients admitted for AP with portosplenomesenteric vein | up to 12 months |
| incidence of digestive ischemia | evaluate the incidence of digestive ischemia of patients admitted for AP with portosplenomesenteric vein | up to 12 months |
| incidence of hepatic ischemia | evaluate the incidence of hepatic ischemia of patients admitted for AP with portosplenomesenteric vein | up to 12 months |
| incidence of pancreatic necrosis | evaluate the incidence of pancreatic necrosis of patients admitted for AP with portosplenomesenteric vein | up to 12 months |